| Value | ₹0.14 Cr |
|---|
NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,066.60
- Market cap
- ₹50,602 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.8×Sector 47.2×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Annual General Meeting
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Gland Pharma Management Change
Gland Pharma Limited announced the resignation of director Wenjie Zhang and the appointment of Xingli Wang as a Non-Executive Non-Independent Director effective October 1, 2026.
Other legal & regulatory announcements
All →Nephrocare Health Services Legal & Regulatory
Nephrocare's Uzbek subsidiary won a court ruling invalidating a ₹14.79 crore tax demand. The tax department must reconsider the audit, and the decision remains appealable.
- Value
- ₹14.79 Cr
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed that its General Manager, Sales & Marketing, was granted bail in an NDPS Act case. The company says the order has no material impact.
Muthoot Finance Legal & Regulatory
Muthoot Finance disclosed a GST Department search and seizure at its Registered Office, conducted October 29-30, 2026. The company states business operations remained unaffected and it is cooperating fully.
Praveg Legal & Regulatory
Praveg received a SEBI penalty order of ₹2 lakh over amalgamation-related non-compliance. The penalty is payable within 45 days.
- Value
- ₹0.02 Cr
Tube Investments of India Legal & Regulatory
Tube Investments received a Punjab Pollution Control Board order imposing ₹39 lakh environmental compensation for partial non-compliance with its Consent to Operate. The company says there is no material impact on its operations or finances.
- Value
- ₹0.39 Cr
Mitsu Chem Plast Legal & Regulatory
Mitsu Chem Plast clarified a late disclosure of its auditor's conversion into an LLP. No auditor change occurred, and the company acknowledged the lapse.